Clinical trials: Lung Cancer Non Small Cell
Lung Cancer
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: EGF816 Gefitinib
- Trial name
- NCT03292133
- Testing
- EGF816, Gefitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
This pilot clinical trial studies whether the levels of certain genes in the tissue and blood are related to how well patients with stage IV non-small cell lung cancer respond to chemotherapy.
- Trial name
- NCT02145078
- Testing
- docetaxel, pemetrexed disodium, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with…
- Trial name
- NCT02394548
- Testing
- Contralateral Esophageal Sparing Technique (CEST)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer (NSCLC)
Single Arm on the Tolerability of Weekly Nab-paclitaxel
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
- Trial name
- NCT01702844
- Testing
- Nab-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one…
- Trial name
- NCT00065182
- Testing
- Topotecan/Docetaxel combination, Docetaxel
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT05513703
- Testing
- Telisotuzumab Vedotin
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 9 people
- Sponsor
- AbbVie
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
- Trial name
- NCT02093962
- Testing
- TH-302 combination with pemetrexed
- Where
- 80 sites in United States, Czechia and 8 more
- Volunteers
- 265 people
- Sponsor
- ImmunoGenesis
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva.
- Trial name
- NCT01378962
- Testing
- erlotinib
- Where
- 10 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung…
- Trial name
- NCT03594747
- Testing
- Tislelizumab, Paclitaxel, Nab-paclitaxel
- Where
- 43 sites in China
- Volunteers
- 360 people
- Sponsor
- BeiGene
Carcinoma, Non-Small-Cell Lung
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy.
- Trial name
- NCT01523587
- Testing
- afatinib, erlotinib
- Where
- 192 sites in United States, Argentina and 21 more
- Volunteers
- 795 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.
- Trial name
- NCT00750698
- Testing
- Entinostat, Erlotinib
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Syndax Pharmaceuticals
Lung Cancer, Tobacco Use Disorder
Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of phenethyl isothiocyanate may prevent lung cancer in people who smoke cigarettes.
- Trial name
- NCT00691132
- Testing
- phenethyl isothiocyanate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of Minnesota
Non-small Cell Lung Cancer
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
The rationale of phase II study of biweekly docetaxel and cisplatin in patients with unresectable NSCLC are follows: First, the optimal dose and schedule of combination with docetaxel and cisplatin are still controversial (3…
- Trial name
- NCT00995761
- Testing
- Docetaxel and Cisplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Gyeongsang National University Hospital
Lung Cancer, Non-Small Cell Lung Cancer
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Background: Over 230,000 new lung cancer cases are diagnosed every year in the United States (U.S.) About 80% of lung cancers are non- small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT04027946
- Testing
- LMB-100, pembrolizumab, Mesothelin Expression
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01948141
- Testing
- nintedanib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Cancer
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Trial name
- AURA2 (NCT02094261)
- Testing
- AZD9291
- Where
- 44 sites in United States, Canada and 6 more
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
A Phase 1b study for participants with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) to participate in 1 of 2 portions of this study.
- Trial name
- PRIMAL (NCT02346370)
- Testing
- PEGylated recombinant human hyaluronidase PH20, Docetaxel
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Halozyme Therapeutics
Lung Cancer
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113386
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 76 sites in United States
- Volunteers
- 19 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small-Cell Lung Cancer
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.
- Trial name
- CheckMate 568 (NCT02659059)
- Testing
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Where
- 32 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.